Progen Prepares For Accelerated Clinical Development Of Anti-Cancer PI-88 Following FDA Meeting (Medical News Today)
Progen Industries (Nasdaq: PGLAF; ASX: PGL) today announced it has received notification from the US Food and Drug Administration (FDA) guiding the accelerated development of its anti-cancer drug PI-88. The FDA has recommended that Progen submit a Special ProtocolAssessment (SPA) detailing the Phase III clinical development plan. [click link for full article]

Oscient Pharmaceuticals Hires Philippe M. Maitre as Senior Vice President and Chief Financial Officer (Business Wire via Yahoo! Finance)
WALTHAM, Mass.----May 22, 2006--Oscient Pharmaceuticals Corporation has hired Philippe M. Maitre as Senior Vice President and Chief Financial Officer. As a senior executive with over 25 years experience at several leading biotechnology, pharmaceutical and contract research organizations, Mr.

Medical Device Manufacturers Surpass 15,000 Companies; FDA Issues New Program (Industry Week)
May 22, 2006 -- Growing from 6,000 companies in 1997, to 15,000 in 2006, medical device manufacturers are producing 100,000 products compared to 84,000 in 1997. With this new influx of products, the Center for Devices and Radiological Health (CDRH) has launched the Medical Device Postmarket Transformation Initiative, which will allow the FDA to identify, analyze and act on problems with medical